http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#Head
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#provenance
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#pubinfo
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion
http://purl.obolibrary.org/obo/DOID_5419
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5419
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01267
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
http://www.w3.org/2000/01/rdf-schema#label
paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia 1 1 adults efficacy was established in three 6 week trials and one maintenance trial 14 1 adolescents ages 12 to 17 efficacy was established in one 6 week trial 14 1 treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and or antidepressants 1 2 efficacy was established in two 6 week trials in adult patients 14 2 paliperidone extended release tablets are indicated for the treatment of schizophrenia see clinical studies 14 1 the efficacy of paliperidone in schizophrenia was established in three 6 week trials in adults and one 6 week trial in adolescents as well as one maintenance trial in adults paliperidone extended release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and or antidepressant therapy see clinical studies 14 2 the efficacy of paliperidone in schizoaffective disorder was established in two 6 week trials in adults
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01267
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#provenance
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#pubinfo
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig
http://purl.org/nanopub/x/hasSignature
St6bopRU4x+cvb2RtyVkzLXkLtFRToqNq4sP5L193HA0UF1OZnz+xyzWQDyS97DCrxU+OMcEkl78CcU4bhRiCltWyV/+mK46xiGLAEj0bTlQ642uvtyokxLOoGHuyohLlm2aD+y8vb8M+j/CCmF7IA0gIpjbvhYZO5Qc4X7PRa8=
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://purl.org/dc/terms/created
2021-06-27T20:38:29.445+02:00
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs